EMBLAVEO Drug Patent Profile

Which patents cover Emblaveo, and what generic alternatives are available?

Emblaveo is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and ninety-five patent family members in fifty-five countries.

The generic ingredient in EMBLAVEO is avibactam sodium; aztreonam. One supplier is listed for this compound. Additional details are available on the avibactam sodium; aztreonam profile page.

DrugPatentWatch^® Generic Entry Outlook for Emblaveo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 7, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EMBLAVEO

International Patents:	195
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EMBLAVEO
What excipients (inactive ingredients) are in EMBLAVEO?	EMBLAVEO excipients list
DailyMed Link:	EMBLAVEO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EMBLAVEO

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

217906

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EMBLAVEO

Drug Class	Monobactam Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for EMBLAVEO

EMBLAVEO is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes			Y	Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes				Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes			Y	Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes				Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes			Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes				Y

Expired US Patents for EMBLAVEO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025

International Patents for EMBLAVEO

When does loss-of-exclusivity occur for EMBLAVEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EMBLAVEO around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1614	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
Argentina	031716	DERIVADOS DE 1-AZA Y 1,3- DIAZABICICLOETANOS Y ANALOGOS, UN PROCEDIMIENTO PARA SU PREPARACION, Y COMPOSICION FARMACEUTICA Y MEDICAMENTOS COMO ANTIBACTERIANOS
Austria	263768
Australia	2001279905
Australia	7990501
Bulgaria	107497
Bulgaria	66094

Supplementary Protection Certificates for EMBLAVEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1480644	300847	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
1480644	PA2016037	Lithuania		PRODUCT NAME: CEFTAZIDIMAS + AVIBAKTAMAS; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
1480644	CA 2016 00059	Denmark		PRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628
1480644	C20160041 00213	Estonia		PRODUCT NAME: TSEFTASIDIIM/AVIBAKTAAM;REG NO/DATE: EU/1/16/1109 28.06.2016
1480644	16C1019	France		PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628
1480644	122016000105	Germany		PRODUCT NAME: CEFTAZIDIM ODER EIN SALZ DAVON MIT AVIBACTAM ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1109 20160624
1480644	93338	Luxembourg		PRODUCT NAME: MELANGE OU ASSOCIATION PHARMACEUTIQUE COMPRENANT COMME INGREDIENTS ACTIFS : (1) CEFTAZIDIME OU UN SEL DE CELUI-CI ET (2) AVIBACTAM OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1109 - ZAVICEFTA - CEFTAZIDIME/AVIBACTAM

Last updated: June 5, 2026

EMBLAVEO (aztreonam-avibactam) market dynamics and financial trajectory

EMBLAVEO is positioned for hospital inpatient growth in complicated infections, with early demand concentrated in settings where clinicians treat multi-drug resistant Gram-negative pathogens. The commercial trajectory depends on (1) formulary adoption and inpatient contracting, (2) the speed and scope of hospital antibiogram shifts toward beta-lactam/beta-lactamase inhibitor regimens, and (3) competitive displacement versus existing anti-Gram-negative options that already have payer coverage and entrenched stewardship pathways. Financial outlook is tied to quarterly conversion from initial awareness to sustained administered volumes, and to how quickly EMBLAVEO expands beyond first-line or salvage use into broader guideline-aligned empiric and targeted use.

The core market dynamic is uptake in “high-acuity, high-resistance” patient segments rather than outpatient volume. That makes revenue more volatile early, with stronger step-ups after major payer or large IDN formulary wins. Net price and rebates will be heavily negotiated, especially against comparators with biosimilar or generic pressure in adjacent categories.

What is EMBLAVEO and what are the main commercial drivers?

EMBLAVEO is the aztreonam plus avibactam combination (intravenous) from AstraZeneca, marketed for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by susceptible Gram-negative bacteria, including beta-lactamase producing organisms.

Key demand drivers

• Hospital use case density. The target populations are typically inpatient with significant resistance burden, supporting faster penetration through hospital pharmacy channels than outpatient products.
• Stewardship fit. The regimen’s coverage profile affects formulary preference among stewardship committees comparing beta-lactam/beta-lactamase inhibitor strategies and carbapenem-sparing approaches.
• Resistance landscape. Avibactam’s inhibition spectrum influences adoption where ESBL- and other beta-lactamase mediated mechanisms are common.
• Clinical workflow. IV dosing convenience and compatibility with existing IV antibiotic order sets can accelerate conversion once physicians and pharmacists standardize use.

Commercial KPI map

• Managed care outcomes: formulary tiering, pharmacy benefit placement for hospital-administered drugs, contract penetration with major group purchasing organizations (GPOs).
• Usage intensity: doses per treated patient, average duration, and replacement of other agents in the same infection episodes.
• Geographic mix: U.S. share tends to drive early revenue volatility; penetration in Europe and select international markets affects mid-term stability.

How fast can EMBLAVEO scale in hospitals based on uptake dynamics?

Hospital scaling for an IV antibiotic generally follows an adoption funnel:

1. ID and pharmacy awareness via stewardship rounds and infectious disease (ID) education.
2. Empiric or targeted uptake in early “use cases” where clinicians have confidence in susceptibility likelihood and resistance mechanism coverage.
3. Institutional standardization through antibiograms and protocol updates.
4. Broader contracting via IDNs and payer contracting cycles.

What drives the speed

• Formulary outcomes and exceptions policy. If EMBLAVEO is placed on preferred tiers with streamlined prior authorization (or clinical criteria aligned with standard resistance testing), adoption is faster.
• Local resistance evidence. Institutions with high prevalence of beta-lactamase producing Gram-negative pathogens convert faster.
• Competitive displacement barriers. If existing regimens are entrenched in clinical pathways, EMBLAVEO can still grow but at a slower conversion rate.

What limits scaling

• Diagnostic dependency. Uptake rises when institutions run rapid AST and resistance mechanism characterization that supports targeted EMBLAVEO use.
• Comparative stewardship preferences. Some hospitals default to carbapenems or established inhibitors, and will adopt EMBLAVEO only when it clearly reduces failures and length of stay.

What market segments should absorb EMBLAVEO first?

Early demand is likely strongest in:

• cUTI/cIAI inpatient cohorts with high rates of resistant Enterobacterales.
• ID-guided salvage therapy when patients fail or are at risk of failure on first-line beta-lactams.
• Facilities with active antimicrobial stewardship that prefer beta-lactam/beta-lactamase inhibitor alternatives to carbapenems.

Revenue sensitivity

• Pricing is less critical early than case selection and institutional contracting. Early revenue can rise sharply after a small number of IDNs switch from comparator regimens in a repeatable protocol.

How does EMBLAVEO compete against other anti-Gram-negative antibiotics?

EMBLAVEO’s competitive set in inpatient anti-Gram-negative therapy typically includes:

• Carbapenems (imipenem-cilastatin, meropenem, ertapenem) where carbapenem-sparing programs may increase interest in alternatives.
• Other beta-lactam/beta-lactamase inhibitor combinations used for ESBL and broader resistance profiles.
• Cephalosporins and other inhibitor strategies depending on local resistance mechanisms and antibiogram patterns.

Competitive dynamic

• EMBLAVEO’s value proposition is strongest in hospitals that treat a meaningful fraction of beta-lactamase driven Gram-negative infections and want to reduce carbapenem exposure without sacrificing coverage.
• Price and contract terms will determine how quickly it displaces comparators even when clinicians accept the coverage rationale.

What are the key financial trajectory assumptions for EMBLAVEO revenue growth?

A credible financial trajectory usually rests on:

• Dose volume ramps: increasing number of treated patients and longer-term repeat use in the same infection episodes.
• Net pricing stability: retention of list price with managed-care discounts and contracting rebates.
• Channel coverage: pharmacy ordering through hospital procurement networks; failure to secure large contracts slows growth.
• Uptake persistence: whether initial launches convert into steady quarterly use once stewardship protocols mature.

Early-stage risk profile

• Volatility by quarter: antibiotics can show step-function growth after protocol adoption but can also stall if clinical criteria narrow.
• Rebate pressure: as more competitors bid into formulary discussions, net realization can compress.
• Share shifts within class: revenue may grow even without dramatic overall market expansion if EMBLAVEO gains share.

What is EMBLAVEO’s revenue exposure to payer and contracting terms?

In the hospital sector, the key is not only payer coverage but the structure of:

• GPO and IDN contracts that determine acquisition cost benchmarks.
• Rebate arrangements tied to performance metrics or formulary volume commitments.
• Institution-specific utilization controls (prior authorization, clinical criteria tied to susceptibility or resistance mechanisms).

Implication for financial trajectory

• Even if physicians want EMBLAVEO, revenue can underperform if large contract wins lag or if institutions require case-by-case approval.
• Conversely, once preferred contracting triggers, revenue can scale quickly due to repeatability.

What is the regulatory and label scope impact on commercial outlook?

Label scope defines the addressable market. EMBLAVEO’s commercial trajectory is linked to:

• Approved indications (e.g., cUTI/cIAI) and any future expansion.
• Dosing and susceptibility criteria that influence clinician willingness to use the drug empirically.
• Any stewardship-friendly evidence supporting its use patterns.

Where label language aligns with routine clinical decision-making, adoption improves; narrow label language can slow conversion.

How do formulary and institutional purchasing decisions change EMBLAVEO adoption?

Institutional adoption can be treated as a contracting game:

• First wins: universities and large IDNs with high patient volumes and active ID programs.
• Second wave: mid-size systems that follow established peers once protocols become standardized.
• Conversion lock-in: once the drug becomes default therapy in protocolized pathways, switching costs rise due to pharmacy system updates and historical outcomes.

Financial effect

• Early quarterly revenue often reflects concentration in a limited set of high-volume institutions.
• Mid-term revenue becomes more stable as formulary footprint expands and utilization becomes more diversified.

What does EMBLAVEO’s competitive landscape imply for price pressure and margins?

In IV antibiotics, margin profiles depend on:

• Net price after rebates and contract concessions.
• Mix between new and repeat patients.
• Volume-based incentives demanded by large customers.

Competitive dynamics with other anti-Gram-negative agents create three price-pressure channels:

1. Formulary leverage when multiple agents cover overlapping pathogen spectra.
2. Stewardship substitution where hospitals prefer one agent per protocol.
3. Payer negotiation intensity as volume grows.

The financial trajectory therefore requires monitoring not just gross sales, but net sales realization trends.

What generic entry risks exist for EMBLAVEO?

Generic entry risk in antibiotics is typically driven by:

• the strength and duration of patent coverage around the drug substance, formulation, and use.
• the time needed for generic development, bioequivalence, and FDA approvals.
• the willingness and ability of generics to pursue paragraph IV challenges if patent estates are vulnerable.

For EMBLAVEO, the practical near-term risk is not generic availability in the current cycle but the strength of patent protection shaping any future challenges. The commercial significance is that if patent barriers hold, revenue can remain protected long enough to recover launch and scale costs. If barriers weaken, revenue can face earlier-than-expected price competition.

How does EMBLAVEO compare with other hospital antibiotics on adoption and scaling?

Compared with many antibiotics, EMBLAVEO’s scaling pattern should reflect:

• Higher friction than established standards during the initial learning period and institutional contracting.
• Potential for faster displacement when stewardship committees can replace carbapenem use without increasing failures.
• Demand concentrated in resistance-heavy centers before broad geographic diffusion.

The comparative advantage becomes clearer when hospitals can show reductions in failures or length of stay, and when susceptibility testing workflows support targeted therapy.

What Key Takeaways does the market dynamics and financial path suggest?

• Revenue growth is contract- and protocol-driven. Stepwise adoption follows formulary wins in large hospital systems and updates to stewardship pathways.
• Net pricing will be negotiated as volume scales. Watch net sales realization rather than list pricing, since rebate intensity usually rises with competitive contracting.
• Competition will shape the trajectory more than baseline market growth. EMBLAVEO’s success is measured by share gains within inpatient anti-Gram-negative therapy rather than growth in total inpatient antibiotics.
• Early volatility is expected. Quarterly performance should reflect adoption funnel conversion and concentration across high-volume institutions.
• Long-term protection depends on patent strength and any future generics pathway. Patent estate stability determines whether revenue can compound beyond the initial launch ramp.

FAQs

1) What hospital purchasing channels most influence EMBLAVEO sales growth?

GPO-driven hospital procurement and large IDN contracting are the primary channels determining volume capture in inpatient IV antibiotic markets.

2) How does antimicrobial stewardship affect EMBLAVEO utilization patterns?

Stewardship committees influence whether EMBLAVEO is used empirically, targeted after AST, or reserved for salvage, which directly affects dose volume and repeat use.

3) What contracting terms most impact EMBLAVEO net sales realization?

Rebate structure, volume commitments, tier placement, and prior authorization requirements tied to clinical criteria affect net realization.

4) How should competitors respond to EMBLAVEO adoption in cUTI and cIAI?

Competitors typically defend through formulary placement, stewardship-aligned protocol adjustments, and competitive contracting aimed at preventing substitution.

5) When do investors typically see stabilization in an IV antibiotic’s revenue trajectory?

Stabilization usually follows broad protocol standardization across a wider footprint of hospitals and consistent repeat utilization patterns, not the initial awareness period.

---

References (APA)

1. AstraZeneca. (n.d.). EMBLAVEO (aztreonam-avibactam) prescribing information and product information.